NuVasive(R) to Exhibit Innovative Products and Procedures at IMAST 2013

NuVasive(R) to Exhibit Innovative Products and Procedures at IMAST 2013 
SAN DIEGO, CA -- (Marketwired) -- 07/10/13 --  NuVasive, Inc.
(NASDAQ: NUVA), a medical device company focused on developing
minimally disruptive surgical products and procedures for the spine,
is excited to announce their participation at the 20th International
Meeting on Advanced Spine Techniques (IMAST) from Wednesday, July 10,
to Saturday, July 13, 2013, in booth #303 at the Vancouver Convention
Center in British Columbia. 
Sponsored by the Scoliosis Research Society, IMAST gathers over 600
world renowned spine surgeons and industry leaders to present and
discuss innovative research and advanced spine technologies in an
international forum. The Scoliosis Research Society is a global
organization dedicated to education, research, and treatment of
spinal deformities. 
"NuVasive is excited to return to IMAST to feature our innovative
products and procedures and to interact with some of the world's
leading spine surgeons," said NuVasive Chairman and CEO Alex
Lukianov. "The meeting will also advance our initiative to
differentiate NuVasive's solutions with clinical evidence, which will
be prominent in several podium and poster presentations and clinical
As an industry sponsor of IMAST, NuVasive will exhibit and
demonstrate the Company's game changing products and procedures,
including XLIF(R), Precept(TM), Armada(R), the PCM(R) Cervical Disc,
and MAS(R) PLIF. 
Additionally, two clinical papers featuring NuVasive's solutions have
been nominated for the prestigious Thomas Whitecloud Award, an award
that recognizes the best basic science and clinical paper at IMAST. 
NuVasive is scheduled to participate in the following events at

--  NuVasive Technical Exhibit Booth #303: The NuVasive exhibit booth will
    feature a number of innovative, minimally disruptive products and
--  NuVasive Hands-on Workshop: NuVasive, along with surgeon proctors
    Behrooz Akbarnia, M.D., Virginie Lafage, M.D., and Juan Uribe, M.D.,
    will host a hands-on workshop on Thursday, July 11, 2013, from 12:00
    to 1:00 p.m. PST. The workshop, titled Anterior Column Realignment:
    MAS Techniques to Restore Sagittal Balance, will discuss the sagittal
    and pelvic parameters and the overall importance of global spinal
--  Clinical Papers: Podium presentations will feature several NuVasive
    products, including the PCM Cervical Disc, XLIF, XLIF ACR(TM)
    (Anterior Column Realignment), and Osteocel(R) Plus. XLIF will also
    be highlighted in four poster presentations.
--  The Thomas Whitecloud Award Nominees: NuVasive is proud to announce
    that two clinical papers have been nominated for the 2013 Thomas
    Whitecloud Award. The clinical paper nominees are: "A Prospective,
    Randomized Clinical Investigation of the PCM Cervical Disc: Five-Year
    Results from US IDE Study," by Dr. Frank Phillips et al., and
    "Comparison of Radiographic Results after Minimally Invasive (MIS),
    Hybrid, and Open Surgery for Adult Spinal Deformity: A Multi-Center
    Study of 184 Patients," by Dr. Raqeeb Haque et al.

For more information on IMAST 2013 please visit:  
For NuVasive press materials please visit:  
 The International Meeting on Advanced Spinal Techniques
(IMAST), sponsored by the Scoliosis Research Society, provides an
international scientific forum for spine professionals to stay
up-to-date on emerging new technologies and techniques. For three
days, spine surgeons and other allied health professionals from
around the world discuss, debate and demonstrate recent advances in
spine surgery. 
About NuVasive 
NuVasive is an innovative global medical device company that is
changing spine surgery with minimally disruptive surgical products
and procedurally integrated solutions for the spine. The Company is
the 4th largest player in the $8.2 billion global spine market. 
NuVasive offers a comprehensive spine portfolio of more than 80
unique products developed to improve spine surgery and patient
outcomes. The Company's principal procedural solution is its Maximum
Access Surgery, or MAS(R) platform for lateral spine fusion. MAS
provides safe, reproducible, and clinically proven outcomes, and is a
highly differentiated solution with fully integrated neuromonitoring,
customizable exposure, and a broad offering of application-specific
implants and fixation devices designed to address a variety of
Having pioneered the lateral approach to spine fusion, NuVasive
continues to be at the forefront of the spine industry's shift toward
less invasive solutions. The Company places a large focus on clinical
research and support of the Society of Lateral Access Surgery, or
SOLAS(R), to expand the body of clinical evidence in support of
NuVasive's minimally disruptive solutions and to drive adoption of
its techniques. The Company's dedication to innovation continues to
spawn game changing technology such as the PCM(R) motion preserving
disc for the cervical spine, XLIF(R) Corpectomy for tumor and trauma,
and Armada(R), which treats adult degenerative scoliosis in a less
invasive fashion. The Company has also developed procedural solutions
that completely redefine and improve upon traditional procedures like
TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are
increasingly being adopted internationally, as the Company lays the
groundwork to continue growing as a global business and to offer
industry-leading, Absolutely Responsive customer service to surgeons
world-wide. NuVasive is focused on becoming a $1 Billion
Start-up(TM); taking market share by maintaining a commitment to
Superior Clinical Outcomes, Speed of Innovation(R), and Absolute
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties that could cause actual growth and
results to differ materially include, but are not limited to those
risks and uncertainties more fully described in NuVasive's press
releases and periodic filings with the Securities and Exchange
Commission. NuVasive's public filings with the Securities and
Exchange Commission are available at NuVasive assumes no
obligation to update any forward-looking statement to reflect events
or circumstances arising after the date on which it was made. 
Investor Contact:
Tina Jacobsen
NuVasive, Inc.
Media Contact: 
Nicole Collins
NuVasive, Inc.
Press spacebar to pause and continue. Press esc to stop.